Skip to content


  1. DynamX Mechanistic Clinical Study, presented CRT 2020
  2. Calculated based on lumen area increase between systole and diastole – Hagen-Poiseuille equation.

  3. Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S. Comparison of zotarolimus‐ and everolimus‐eluting coronary stents: final 5‐year report of the RESOLUTE all‐comers trial. Circ Cardiovasc Interv. 2015; 8:e002230.

  4. Gyöngyösi M, Yang P, Khorsand A, et al. Longitudinal Straightening Effect of Stents Is an Additional Predictor for Major Adverse Cardiac Events. J Am Coll Cardiol 2000;35:1580-9.
  5. LTFU after 81 Days

  6. LTFU after 304 Days

  7. Data on file at Elixir Medical

  8. COVER-OCT Trial – Kim et al. Am Heart J 2012; 163:601

  9. Resolute all Comers: Gutierrez-Chico et al EHJ, 2011; 32:2454

  10. DESSOLVE-1 Trial – Attizzani et al. Am J Cardiol 2013; 112-1557

  11. Iqbal, J, Verheye, S, Abizaid, A, Ormiston, J, de Vries, T, Morrison, L & Serruys, PW. DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016;12(11), e1336

  12. Chien S. Am J Physiol Heart Circ Physiol. 2007; 292: H1209-H1224.

  13. Stone GW, Kimura T, Gao R, et al. JAMA Cardiol. 2019 Dec 1;4(12):1261-1269.

  14. Kufner S, Joner M, Thannheimer A, et al. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease – Results From the ISAR-TEST 4 Randomized Trial. Circulation. 2019;139:325–333.
  15. Verheye S, Vrolix M, Montorfano M, et al. Twelve-month clinical and imaging outcomes of the uncaging DynamX Bioadaptor System. EuroIntervention 2020; Jaa-835, 2020, doi: 10.4244/EIJ-D-20-00763.

  16. Serruys P, et al,  A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial., EuroIntervention 2006.

  17. Meredith IT, et al, Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC (2009).

  18. Meredith IT, Whitbourn R, Scott D, et al, PLATINUM QCA: EuroIntervention. 2011.

  19. Windecker, S. et al, (LEADERS): a randomised non inferiority trial; The Lancet 2008; 372 No. 9644: 1163-1173.

  20. Windecker S. et al, BioFlow II Trail, Circulation: Cardiovascular Intervention 2015.

  21. Meredith IT, Primary Endpoint Results of the EVOLVE Trial: A Randomized Evaluation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent, 2012.

  22. DynamX Mechanistic Clinical Study 24 Month Results, presented Singapore Live 2021
  23. LTFU after 344 Days; 2 missed visits
  24. DynamX Mechanistic Clinical Study 36 Month Results, presented TCT 2021
  25. LTFU after 738 days and 749 days

PMN 594 Rev C